Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability

During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lizhou, More, Kunal R., Ojha, Amrita, Jackson, Cody B., Quinlan, Brian D., Li, Hao, He, Wenhui, Farzan, Michael, Pardi, Norbert, Choe, Hyeryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567765/
https://www.ncbi.nlm.nih.gov/pubmed/37821446
http://dx.doi.org/10.1038/s41541-023-00751-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567765/
https://www.ncbi.nlm.nih.gov/pubmed/37821446
http://dx.doi.org/10.1038/s41541-023-00751-6

Ejemplares similares